The higher in vivo efficacy of our nanosystem could be ascribable to the combined contribution of active tumor targeting that exploits the selective TfR1 expression on HNSCC cells, and the increased delivery into the cell nucleus as observed previously. Here, TFRC is linked to head and neck squamous cell carcinoma.